Fluoxetine efficacy in treatment resistant depression.

Abstract	1. As many as 30% of depressed patients fail to respond to antidepressant drug therapy, and at least 60%-75% will not achieve complete recovery. Recently, several studies have suggested that newer, "second generation" antidepressants might be beneficial in treatment resistant depression (TRD). In the present study the authors examined the potential utility of fluoxetine in TRD by comparing its efficacy in patients with and without a prior history of antidepressant response. 2. 149 patients with MDD received fluoxetine 20mg daily for a minimum of 5 weeks: 43 (29%) had never responded to drug therapy (TRD patients), 41 (28%) did have a prior drug response (non-TRD patients) and 65 (44%) had never received any antidepressant treatment. Clinical response was defined as a > or = 50% reduction in baseline Hamilton Depression Rating score plus a final score < 7. 3. Compared to non-TRD patients, the TRD patients were more likely to have unipolar depression (p = 0.002), a chronic episode of > 2 years duration (p < 0.0001), a later age of illness onset (p < 0.0001), fewer prior episodes (p < 0.0001) and fewer prior drug treatments (p = 0.04). Overall, the response rate to fluoxetine was slightly greater in the non-TRD patients (76%) compared to the TRD patients (56%); however, this difference did not achieve statistical significance. 4. The present observations suggest that fluoxetine treatment of adequate duration may be beneficial for some patients with a prior history of refractory depression.
Authors	J D Amsterdam, G Maislin, L Potter
Journal	Progress in neuro-psychopharmacology & biological psychiatry (Prog Neuropsychopharmacol Biol Psychiatry) Vol. 18 Issue 2 Pg. 243-61 (Mar 1994) ISSN: 0278-5846 [Print] England
PMID	8208976 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Fluoxetine
Topics	Adult Aged Depressive Disorder (drug therapy, psychology) Drug Resistance Female Fluoxetine (therapeutic use) Humans Male Middle Aged Psychiatric Status Rating Scales

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!